...
首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy.
【24h】

Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy.

机译:恐慌症患者的血清脑源性神经营养因子(BDNF)水平:作为对集体认知行为疗法反应的生物学预测指标。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Little is known about biological predictors of treatment response in panic disorder. Our previous studies show that the brain-derived neurotrophic factor (BDNF) may play a role in the pathophysiology of major depressive disorders and eating disorders. Assuming that BDNF may be implicated in the putative common etiologies of depression and anxiety, the authors examined serum BDNF levels of the patients with panic disorder, and its correlation with therapeutic response to group cognitive behavioral therapy (CBT). Group CBT (10 consecutive 1 h weekly sessions) was administered to the patients with panic disorder after consulting the panic outpatient special service. Before treatment, serum concentrations of BDNF and total cholesterol were measured. After treatment, we defined response to therapy as a 40% reduction from baseline on Panic Disorder Severity Scale (PDSS) score as described by [Barlow, D.H., Gorman, J.M., Shear, M.K., Woods, S.W., 2000. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 283, 2529-2536]. There were 26 good responders and 16 poor responders. 31 age- and sex-matched healthy normal control subjects were also recruited in this study. The serum BDNF levels of the patients with poor response (25.9 ng/ml [S.D. 8.7]) were significantly lower than those of the patients with good response (33.7 ng/ml [S.D. 7.5]). However, there were no significant differences in both groups of the patients, compared to the normal controls (29.1 ng/ml [S.D. 7.1]). No significant differences of other variables including total cholesterol levels before treatment were detected between good responders and poor responders. These results suggested that BDNF might contribute to therapeutic response of panic disorder. A potential link between an increased risk of secondary depression and BDNF remains to be investigated in the future.
机译:关于恐慌症中治疗反应的生物学预测因素知之甚少。我们以前的研究表明,脑源性神经营养因子(BDNF)可能在主要抑郁症和进食障碍的病理生理中起作用。假设BDNF可能与抑郁和焦虑的常见病因有关,作者检查了恐慌症患者的血清BDNF水平,及其与对集体认知行为疗法(CBT)的治疗反应的相关性。在咨询恐慌门诊特别服务后,对恐慌症患者进行了CBT组治疗(连续10次,每周1小时)。治疗前,测量血清BDNF和总胆固醇。治疗后,我们将治疗反应定义为恐慌症严重程度量表(PDSS)评分较基线水平降低40%,如[Barlow,DH,Gorman,JM,Shear,MK,Woods,SW,2000年所述。认知行为疗法,丙咪嗪或它们的组合治疗恐慌症:一项随机对照试验。贾玛283,2529-2536]。有26位好响应者和16位差响应者。本研究还招募了31名年龄和性别匹配的健康正常对照受试者。反应差的患者(25.9 ng / ml [S.D. 8.7])的血清BDNF水平显着低于反应好的患者(33.7 ng / ml [S.D. 7.5])。但是,与正常对照组(29.1 ng / ml [S.D. 7.1])相比,两组患者均无显着差异。在良好反应者和较差反应者之间,未检测到其他变量(包括治疗前的总胆固醇水平)的显着差异。这些结果表明BDNF可能有助于恐慌症的治疗反应。继发性抑郁的风险增加与BDNF之间的潜在联系有待于未来研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号